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Retinoic acid (RA) synthesized by Raldh3 in the frontonasal surface ectoderm of chick embryos has been suggested to function in early
forebrain patterning by regulating Fgf8, Shh, and Meis2 expression. Similar expression of Raldh3 exists in E8.75 mouse embryos, but Raldh2
is also expressed in the optic vesicle at this stage suggesting that both genes may play a role in early forebrain patterning. Furthermore, Raldh3
is expressed later in the forebrain itself (lateral ganglionic eminence; LGE) starting at E12.5, suggesting a later role in forebrain neurogenesis.
Here we have analyzed mouse embryos carrying single or double null mutations in Raldh2 and Raldh3 for defects in forebrain development.
Raldh2−/−;Raldh3−/− embryos completely lacked RA signaling activity in the early forebrain, but exhibited relatively normal expression of Fgf8,
Shh, and Meis2 in the forebrain. Thus, we find no clear requirement for RA in controlling expression of these important forebrain patterning
genes, but Raldh3 expression in the frontonasal surface ectoderm was found to be needed for normal Fgf8 expression in the olfactory pit. Our
studies revealed that later expression of Raldh3 in the subventricular zone of the LGE is required for RA signaling activity in the ventral
forebrain. Importantly, expression of dopamine receptor D2 in E18.5 Raldh3−/− embryos was essentially eliminated in the developing nucleus
accumbens, a tissue lying close to the source of RA provided by Raldh3. Our results suggest that the role of RA during forebrain development
begins late when Raldh3 expression initiates in the ventral subventricular zone.
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Inductive interactions are crucial for anteroposterior (Shima-
mura and Rubenstein, 1997; Storm et al., 2006) and dorsoventral
(Gunhaga et al., 2003; Lupo et al., 2006) regionalization of the
forebrain during early development. Important signals include
secreted proteins generated by Fgf8 expressed anteriorly in the
anterior neural ridge, Shh expressed ventrally in the prechordal
plate mesendoderm, and Wnt genes expressed dorsally at the
junction between the forebrain and epidermal ectoderm.
Retinoic acid (RA), a small molecule derived from vitamin A
that serves as a ligand for nuclear RA receptors, has also been
proposed to play a cell–cell signaling role in forebrain
regionalization (Halilagic et al., 2003; Marklund et al., 2004;
Ribes et al., 2006; Schneider et al., 2001). However, a clearly⁎ Corresponding author. Fax: +1 858 646 3195.
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Early studies in chick embryos reported that Raldh3 expression
in the frontonasal surface ectoderm at stage 10may be a potential
source of RA for the forebrain and that embryos treated with RA
receptor antagonists at that stage exhibit a complete loss of Fgf8
and Shh expression in the forebrain field (Schneider et al., 2001).
In contrast, forebrain defects and loss of Shh expression
observed in vitamin A deficient quail embryos were proposed
to be due to an earlier effect of RA generated in the anterior
endoderm by Raldh2 at stages 3–4 (Halilagic et al., 2003).
However, null mice lacking RA synthesis controlled by Raldh2
displayed relatively mild reductions in Fgf8 and Shh expression
in the forebrain field, and these effects were apparent only at later
stages (Ribes et al., 2006). Other studies of chick embryos
treated with RA receptor antagonists reported a loss of Meis2
expression in the intermediate region of the forebrain (progenitor
of the striatum) leading to the hypothesis that RA might control
intermediate character along the dorsoventral axis, with SHH
regulating ventral character and FGF plus WNT regulating
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examinations of forebrain RA function, RA plays a well-
established role in the development of the hindbrain and spinal
cord. RA is required during early posteriorization of the central
nervous system to generate the posterior hindbrain (Dupé and
Lumsden, 2001; Gavalas and Krumlauf, 2000; Maden et al.,
1996; Niederreither et al., 2000; Sirbu et al., 2005) and spinal
cord (Liu et al., 2001; Molotkova et al., 2005), plus RA is
required for dorsoventral patterning of the spinal cord to
generate motor neurons (Del Corral et al., 2003; Novitch et al.,
2003; Wilson et al., 2004) and later for specifying motor neuron
sub-type identity (Sockanathan and Jessell, 1998; Sockanathan
et al., 2003; Vermot et al., 2005).
In order to ascertain a role for RA in forebrain development
(if any), one approach is to establish the identity and expression
patterns of RA receptors as well as enzymes that may synthesize
RA that could reach the forebrain (RA sources), then establish
the locations where RA signaling activity occurs in the forebrain
(RA target tissues). RA serves as a ligand for three nuclear RA
receptors (RAR) that bind DNA as heterodimers with retinoid X
receptors (RXR); binding of all-trans-RA to the RAR
component of RAR/RXR heterodimers is necessary for early
development, whereas the isomer 9-cis-RA (which can bind
RXR under pharmacological conditions) is unnecessary and
undetectable under physiological conditions (Mic et al., 2003).
During the early stages of central nervous system development,
expression of RARα and RARγ is widespread throughout the
mouse embryo including the developing forebrain, but RARβ
expression is limited to hindbrain and spinal cord (Mollard et al.,
2000). Thus, RA signaling could potentially occur throughout
the early forebrain due to the presence of RARα and RARγ. At
later stages, RARβ is expressed at high levels in the lateral
ganglionic eminence (LGE) which gives rise to the striatum
located in the ventral forebrain (Mollard et al., 2000). However,
the location of RA signaling will also depend on the location of
RA synthesis which is not as widespread as RAR expression.
The final step of all-trans-RA synthesis (oxidation of
retinaldehyde to RA) is carried out by retinaldehyde dehydro-
genases encoded by Raldh1, Raldh2, and Raldh3 (Aldh1a1,
Aldh1a2, and Aldh1a3—Mouse Genome Informatics)
expressed in non-overlapping patterns (Mic et al., 2002;
Niederreither et al., 1999; Reijntjes et al., 2005). In mouse
embryos, two enzymes could serve as RA sources for the early
forebrain as Raldh2 is expressed in the optic vesicle starting at
E8.25 and Raldh3 is expressed in the frontonasal surface
ectoderm starting at E8.5 (Li et al., 2000; Mic et al., 2002). In
chick embryos, Raldh3 could serve as an early RA source as it
exhibits frontonasal expression similar to mouse, but Raldh2 is
not expressed in the optic vesicle or anywhere else rostrally
(Blentic et al., 2003). Studies on quail embryos reported that
Raldh2 is transiently expressed at stages 3–4 in the hypoblast
and anterior endoderm (Halilagic et al., 2003), but such
expression was not observed in mouse or chick embryos. In
both mouse and chick embryos, Raldh1 expression in the head
initiates at a later stage and is limited to the dorsal retina. The
RARE-lacZ RA-reporter transgene has been particularly useful
for determining RA target tissues in mouse embryos (Rossant etal., 1991). RARE-lacZ expression is first observed at E7.5 in the
posterior mesoderm where Raldh2 is first expressed (Sirbu et al.,
2005). Anterior expression of RARE-lacZ does not occur until
E8.25 when Raldh2 expression initiates in the optic vesicle
(Wagner et al., 2000). Crosses of RARE-lacZ mice with Raldh
null mice can be used to determine the contribution of each
Raldh gene for RA signaling activity in a given tissue. For
instance, wild-type embryos carrying RARE-lacZ exhibit RA
activity throughout much of the head at E8.75 during early
forebrain development, and Raldh2−/− embryos carrying RARE-
lacZ lose all RA activity in the forebrain while retaining RA
activity in the frontonasal surface ectoderm where Raldh3 is
expressed (Mic et al., 2004). As frontonasal expression of
Raldh3 does not generate RA that reaches the forebrain
neuroepithelium, this source of RA may be designed for another
developmental purpose.
Raldh3 may play a much later role in ventral forebrain
development as it is specifically expressed in the LGE starting
at E12.5 in the mouse (Li et al., 2000). Furthermore, Raldh3
may be responsible for RA detected in radial glia in the LGE
(Toresson et al., 1999) and Raldh3 expression is under the
control of the homeobox gene Gsh2 which plays an essential
role in the development of the LGE which gives rise to the
striatum (Waclaw et al., 2004). Here, Raldh2 and Raldh3 single
and double null mutant embryos have been analyzed to provide
further insight into the role of RA during early or late forebrain
development. We do not find clear evidence of an RA signaling
requirement during early forebrain patterning, but RA generated
by Raldh3 in the LGE was found to be necessary for later stages
of forebrain development.
Materials and methods
Raldh null mice
Several Raldh mutant mice have been previously described including
Raldh2−/− embryos which exhibit midgestation lethality (Mic et al., 2002) and
Raldh3−/− embryos which exhibit postnatal lethality just after birth (Molotkov et
al., 2006). Generation of compound Raldh2–RAldh3 null mice was performed
by mating of adult mice heterozygous for both null mutations. Embryos derived
from timed matings were genotyped by PCR analysis of yolk sac DNA.
Following mating, noon on the day of vaginal plug detection was considered
embryonic day 0.5 (E0.5).
Rescue of Raldh2−/− early lethality with dietary RA supplementation
Rescue of Raldh2−/− embryos and Raldh2−/−;Raldh3−/− embryos bymaternal
dietary RA supplementation was performed similar to a previous description
(Molotkov et al., 2006) with an RA dose demonstrated to be in the normal
physiological range (Mic et al., 2003). Briefly, all-trans-RA (Sigma Chemical
Co.) was dissolved in corn oil andmixedwith powderedmouse chow to provide a
final concentration of 0.1 mg/g for treatment from E6.75 to E8.5. In some cases
embryos were analyzed when the mother was still on the RA-supplemented diet,
but in other cases the mother was returned to standard mouse chow at E8.5 and
embryos were analyzed at E10.5. Such food was prepared fresh twice each day
(morning and evening) and provided ad libitum.
In situ hybridization and immunohistochemistry
Whole-mount in situ hybridization of mouse embryos was performed using
digoxigenin-labeled antisense RNA probes as described previously (Wilkinson,
Fig. 1. Location of rostral RA synthesis and RA activity in the developing mouse
embryo. (A–B) Detection of Raldh2 and Raldh3 mRNAs at E8.75. (C–D)
RARE-lacZ expression at E9.0 and transverse section demonstrating RA activity
throughout the forebrain. (E–F) Detection of Raldh2 and Raldh3 mRNAs at
E10.5. e, eye; f, forebrain telencephalic vesicle; ol, olfactory pit; op, optic
vesicle.
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2002). We also performed whole-mount in situ hybridization on sections of
embryonic forebrain as follows. The whole brains of E14.5 or E18.5 embryos
were dissected and fixed overnight in 4% paraformaldehyde at 4 °C. On the next
day brains were washed for 20 min at 4 °C in phosphate-buffered saline
containing 0.1% Tween-20, embedded in 3% agarose, and sectioned on a
vibratome at 150 μm. Sections were individually collected, dehydrated, and
stored in 100% methanol at −20 °C until analysis. The remaining steps for in
situ hybridization of these whole-mount sections were performed as described
previously (Wilkinson, 1992). Immunohistochemistry was performed on
paraffin sections as previously reported (Haselbeck et al., 1999) using an
antibody against mouse DARPP-32, 1:1000 (Chemicon).
Detection of retinoic acid
Embryos carrying the RARE-lacZ RA-reporter transgene which places lacZ
(encoding β-galactosidase) under the transcriptional control of a retinoic acid
response element (RARE) were used to detect RA in E8 whole-mount embryos
(Rossant et al., 1991). Stained embryos were embedded in 3% agarose and
sectioned at 50 μm with a vibratome. For detection of RA in E14.5 embryonic
forebrain tissues, an RA bioassay was performed utilizing Sil-15 F9-RARE-lacZ
RA-reporter cells (Wagner et al., 1992). Dissected tissue explants of equal size
from wild-type and mutant embryos were first incubated overnight in tissue
culture medium to allow diffusion of RA into the medium, and then this
conditioned medium was placed upon a confluent lawn of F9-RARE-lacZ RA-
reporter cells followed by detection of β-galactosidase activity as described
previously (Luo et al., 2004).
Results
Two potential RA sources during mouse early forebrain
development
At E8.75, mouse embryos express Raldh2 in the optic
vesicles and Raldh3 in the frontonasal surface ectoderm (Figs.
1A–B). At E9.0, the RA-reporter transgene RARE-lacZ is
expressed throughout the optic vesicles and frontonasal surface
ectoderm, as well as the forebrain neuroectoderm that will form
the telencephalic vesicles (Figs. 1C–D). By E10.5, Raldh2
expression is no longer observed in the eye or anywhere nearby
the forebrain, plus Raldh3 expression in the frontonasal surface
ectoderm is now limited to the olfactory pits and Raldh3 is now
expressed in the eye (Figs. 1E–F). Thus, the mouse has two
potential sources of RA located outside of the developing
telencephalon that can provide RA to this tissue. However,
previous studies of Raldh2−/− embryos carrying RARE-lacZ
revealed that RA activity is no longer observed in the forebrain
neuroectoderm whereas Raldh3 mRNA and RA activity is still
observed in the frontonasal surface ectoderm (Mic et al., 2004).
These findings demonstrate that in mouse embryos Raldh3
does not provide RA to early telencephalic progenitor cells, but
that Raldh2 does. However, a role for Raldh2 in providing RA
for early telencephalon development is not conserved as avian
embryos do not express Raldh2 in the optic vesicles (Blentic
et al., 2003).
Lack of RA requirement for Fgf8 and Shh expression in early
forebrain
Previous studies suggested that RA is necessary for
expression of Fgf8 and Shh in the forebrain field (Halilagicet al., 2003; Ribes et al., 2006; Schneider et al., 2001). In order
to follow up on these findings, we generated mouse embryos
lacking all RA synthesis. RA activity was examined in Raldh2
and Raldh3 single and double null embryos carrying RARE-
lacZ at E8.75; Raldh2−/− embryos are still relatively healthy at
E8.75, but deteriorate quickly after that due to somite and
cardiovascular defects (Niederreither et al., 1999); on the other
hand, Raldh3−/− embryos survive to birth (Dupé et al., 2003).
Whereas Raldh3−/− embryos exhibited no significant decrease
in forebrain RA activity compared to wild-type, Raldh2−/−
embryos exhibited a large reduction in forebrain RA activity
and Raldh2−/−;Raldh3−/− embryos exhibited no forebrain RA
activity (Figs. 2A–D). Fgf8 was still expressed in the anterior
neural ridge of E8.75 Raldh2−/−;Raldh3−/− embryos completely
lacking RA activity (Figs. 2E–H); an apparent slight reduction
in Fgf8 expression is likely due to the entire head being slightly
smaller in embryos carrying Raldh2−/− due to deterioration of
embryonic health. Raldh2−/−;Raldh3−/− embryos exhibited
relatively normal expression of Shh in the prechordal plate at
E8.75 (Figs. 2I–L). These results demonstrate that Raldh2 and
Raldh3 are responsible for all RA activity observed in the early
forebrain, but that elimination of this RA does not have a
Fig. 2. Loss of rostral RA activity does not affect Fgf8 or Shh expression except in olfactory pit. All embryos shown are at E8.75 and are unrescued (not treated with
RA). (A–D) RARE-lacZ expression demonstrating partial loss of RA activity in Raldh2 null mutant and complete loss of RA activity in Raldh2–RAldh3 double null
mutant (R2−/−:R3−/−). (E–H) Fgf8 expression and (I–L) Shh expression are not significantly altered following complete loss of RA; arrows point to the relevant
expression domains in the forebrain field. (M–N) Fgf8 mRNA in Raldh3−/− olfactory pit (ol) exhibits abnormal ventral extension indicated by an asterisk.
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field at E8.75.
Raldh3 is required in the olfactory pit
As our findings suggest that Raldh3 expression in the
frontonasal surface ectoderm is not required for forebrain
development, we examined whether Raldh3 plays a function
locally in the olfactory pit where its expression becomes
concentrated by E10.5 (Fig. 1F). Previous studies on chick
embryos treated with the RA synthesis inhibitor citral suggested
that RA is required to upregulate Fgf8 expression in the
olfactory pit (Song et al., 2004). This is in contrast to previous
studies on Raldh3−/− mouse embryos which reported that
endogenous RA functions to downregulate Fgf8 expression
along the ventral edge of the olfactory pit; this defect was
proposed to contribute to blockage of the nasal passages leading
to lethality just after birth (Dupé et al., 2003). Examination of
our Raldh3−/− embryos at E10.75 confirmed that Fgf8
expression is upregulated along the ventral edge of the olfactory
pit (Figs. 2M–N). Previous examination of our Raldh3−/−
embryos carrying RARE-lacZ has demonstrated that suchembryos have no RA activity in the olfactory pit at E9.75–
E11.5, thus correlating with the observations that Raldh2
expression in the eye field ends soon after E9.5 and RA activity
generated by Raldh1 expression in the dorsal eye is too weak to
reach the olfactory pit (Molotkov et al., 2006). Thus, our
findings and those of others (Dupé et al., 2003) indicate that the
function of Raldh3 in the frontonasal surface ectoderm is to
generate RA required to regulate olfactory pit development
rather than forebrain development.
RA is unnecessary for Meis2 expression in the forebrain
Meis2 is a homeobox gene expressed specifically in the
intermediate region of the forebrain which gives rise to the LGE
and later the striatum (Toresson et al., 1999). Previous studies on
chick embryos treated with an RAR antagonist suggested that RA
is necessary for expression of Meis2 in the intermediate region of
the telencephalon (Marklund et al., 2004). As telencephalicMeis2
expression does not begin in mouse embryos until E9.5, whereas
Raldh2−/− embryos exhibit lethality after E8.75 (Niederreither et
al., 1999), we performed a mild RA treatment on Raldh2−/−
embryos to rescue early lethality. Previous studies have shown that
Fig. 3. Loss of rostral RA activity does not affect expression of Meis2, a marker of forebrain intermediate character. (A–B) Rescue of Raldh2−/− early lethality by
maternal RA treatment from E6.75 to E8.5 does not stimulate RA activity in the forebrain or other head tissues. (C–F) Coronal sections through the telencephalon
showing that Meis2 expression is not significantly affected in E10.5 single mutants or Raldh2–Raldh3 double null mutants (R2−/−:R3−/−) rescued by maternal RA
treatment from E6.75 to E8.5 (which does not stimulate RA activity in the forebrain as shown in panel A). f, forebrain telencephalic vesicles.
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E6.75 to E8.5 is sufficient to rescue somitogenesis defects that
contribute to lethality, and that the administered RA functions
primarily in the posterior neuroectoderm and node ectoderm as
opposed to throughout the embryo (Sirbu and Duester, 2006).
Here, we show that such RA treatment does not stimulate RA
activity in the forebrain as shown by the analysis of RA activity in
E8.5 rescued Raldh2−/− embryos carrying RARE-lacZ (Figs. 3A–
B). Thus, this treatment allows one to look at later defects in
Raldh2−/− embryos similar to a conditional null allele. Raldh2 and
Raldh3 single and double null embryos rescued in this fashion
were examined for Meis2 expression at E10.5 when the
telencephalic vesicles are well-established. Meis2 expression was
still observed in the intermediate region of the telencephalon in all
embryos examined including Raldh2−/−;Raldh3−/− embryos that
lack RA activity in the forebrain; telencephalon morphology was
also relatively normal (Figs. 3C–F). These findings suggest that
RA is not required to initiate Meis2 expression in the forebrain.
Raldh3 is required for RA activity detected in the LGE
Raldh3 expression initiates in the mouse forebrain at E12.5
specifically in the LGE (Li et al., 2000). Here, we demonstrate that
Raldh3 expression at E14.5 is localized in the subventricular zone
of the LGE (Fig. 4A). RA has previously been detected in the
forebrain specifically in the LGE but not the medial ganglionic
eminence (MGE) or cortex (Liao et al., 2005; Luo et al., 2004;
Toresson et al., 1999). Those studies employed tissue explantbioassays to detect RA as the RARE-lacZ transgenic mouse does
not express lacZ in the LGE or ventral forebrain (Luo et al., 2004).
Furthermore, the RARE-lacZ transgenic mouse expresses lacZ
ectopically in the cortex where no RA is detected using tissue
explant bioassays, and RARE-lacZ expression persists in the
cortex of Raldh1−/−;Raldh2−/−;Raldh3−/− triple null embryos
(Molotkov et al., 2006). Thus, RARE-lacZ expression in transgenic
mice is for some unknown reason not useful to monitor RA
activity during late forebrain development.
Using a tissue explant RA bioassay previously reported (Luo
et al., 2004), we found that all RA activity detectable in the
wild-type LGE at E14.5 was eliminated in Raldh3−/− embryos
(Figs. 4D–E). As controls we found much lower RA activity in
the Raldh3−/− eye compared with wild-type (Figs. 4B–C); this
is consistent with loss of RA synthesis by Raldh3 expressed in
the ventral retina, but retention of RA synthesis by Raldh1
expressed in the dorsal retina (Molotkov et al., 2006). We also
found that wild-type cortex contained no RA activity, and this
was unchanged in Raldh3−/− embryos (Figs. 4F–G). These
findings demonstrate that Raldh3 is responsible for RA detected
specifically in the LGE.
Endogenous RA upregulates RARβ expression in the LGE
(striatum)
Although RARβ is normally expressed only in the striatum,
RA treatment of mouse striatum and cortex tissue explants
results in the induction of RARβ expression in both (Liao et al.,
Fig. 4. Raldh3 is responsible for RA detectable in ventral forebrain at later
stages. (A) Coronal section through E14.5 forebrain demonstrates that Raldh3
mRNA is localized to the subventricular zone (SVZ) of the lateral ganglionic
eminence (LGE). (B–G) F9-RARE-lacZ RA-reporter cells exposed to super-
natants of cultured E14.5 embryonic tissues; in wild-type tissues RA activity is
detected in the eye and LGE but not cortex; in Raldh3−/− tissues RA activity is
greatly reduced in the eye and not detected in the LGE.
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significant decrease in RARβ expression in the striatum,
particularly ventrally in the region encompassing the nucleus
accumbens (Figs. 5A–B). Our studies now demonstrate that
endogenous RA generated by Raldh3 in the LGE (striatum) is
required to upregulate RARβ to achieve its normal level of
expression in the striatum. However, some RARβ expression
remains in the absence of Raldh3 function.
Raldh3 is not required to generate DARPP-32 striatal
projection neurons
Gsh2−/− embryos, lacking a homeobox gene important for
striatal development, exhibit a 50% reduction in striatal
volume and a large reduction in DARPP-32 immunoreactivity
which marks striatal projection neurons (Waclaw et al., 2004).
Gsh2−/− embryos also exhibit a reduction in forebrain Raldh3
expression, and RA treatment of these embryos from E11.5 to
E17.5 to replace the missing RA was reported to increase
DARPP-32 immunoreactivity at E18.5, although striatalvolume was not increased (Waclaw et al., 2004). We found
that DARPP-32 immunostaining was not significantly changed
in Raldh3−/− versus wild-type striatum at E18.5; also
Raldh3−/− forebrains did not exhibit a significant decrease in
striatal volume compared to wild-type (Figs. 5C–D). Thus, we
find no evidence that endogenous RA generated by Raldh3 is
necessary for DARPP-32 neuron differentiation.
Raldh3 is required for dopamine receptor D2 expression in
nucleus accumbens
Adult mice carrying RA receptor mutations were previously
reported to exhibit impaired locomotion and reduced expression
of dopamine receptor D2 (Drd2) specifically in the ventral
striatum, suggesting that the nucleus accumbens may be a target
of RA action (Krezel et al., 1998). The nucleus accumbens can
be visualized at E18.5 as a site of high Drd2 expression in the
ventromedial region of the striatum (Corbin et al., 2000). We
compared Drd2mRNA in serial coronal sections of E18.5 wild-
type and Raldh3−/− forebrains. Drd2 expression was observed
in a wide swath across the anteroposterior axis of both wild-type
and Raldh3−/− striatum, and this was mostly unchanged in the
mutant except that high-level Drd2 expression in the region
where the nucleus accumbens develops was not observed (Figs.
6A–B; Supplementary Fig. 1). Low-level expression of Drd2 in
this region suggests that neurons comprising the nucleus
accumbens do exist, but detailed studies on neuronal migration
are needed to directly address this question. In addition to the
specific loss of Drd2 expression in the nucleus accumbens, a
reduction in Drd2 expression is also observed in more
dorsomedial tissue adjacent to the subventricular zone of the
Raldh3−/− forebrain (Figs. 6A–B). In a comparable E18.5 wild-
type coronal section at the same anteroposterior position, robust
Raldh3 expression is observed in the subventricular zone of the
ventral striatum located medial to the striatum and just dorsal to
the nucleus accumbens (compare Figs. 6A and C). In an
equivalent section, RARβ expression is observed throughout
the striatum and nucleus accumbens (Fig. 6D).
Examination of sagittal sections through E18.5 wild-type
forebrains demonstrated that Raldh3 mRNA is limited to a
small domain along the anteroposterior axis of the striatum near
the anterior end of the ventricle, located just dorsal to where the
nucleus accumbens is located (Fig. 6E). Sagittal sections
revealed that RARβ mRNA is localized to a similar
anteroposterior domain as Raldh3, although extending further
ventrally into the region where the nucleus accumbens resides
(Fig. 6F). Altogether, these findings indicate that RA generated
by Raldh3 is required for high-level expression of Drd2 in the
nucleus accumbens, but not for Drd2 expression in the rest of
the forebrain. The expression domains of Raldh3 and RARβ are
consistent with this region of the forebrain being a robust site of
RA signaling.
Discussion
Previous studies in avian embryos utilizing either RAR/RXR
antagonists or vitaminA deficiency suggested that RA generated
Fig. 5. RA generated by Raldh3 regulates RARβ but not DARPP expression in LGE. All panels are coronal sections through the forebrain. (A–B) At E18.5,
RARβ mRNA is greatly reduced in the striatum (LGE) of an Raldh3−/− (R3−/−) embryo particularly in the ventral region including the nucleus accumbens. (C–D)
DARPP-32 immunohistochemistry at E18.5 demonstrating no significant difference between wild-type and Raldh3−/− forebrain. ac, anterior commissure; cx,
cortex; LGE, lateral ganglionic eminence; na, nucleus accumbens; str, striatum.
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development to induce expression of genes needed to establish
regionalization; i.e. Raldh2 in anterior endoderm at stage 3 was
proposed to control Shh (Halilagic et al., 2003), Raldh3
expressed in frontonasal surface ectoderm at stage 10 was
proposed to control Fgf8 and Shh (Schneider et al., 2001), and
Raldh3 expressed in frontonasal surface ectoderm at stage 14
was proposed to control Meis2 in the intermediate region of the
telencephalon (Marklund et al., 2004). Previous studies on
Raldh2−/− mouse embryos reported that expression of Fgf8 and
Shh expression is initially unaffected at E8.75 but is reduced by
E9.5 (Ribes et al., 2006). As Raldh3 expression remains in
Raldh2−/− embryos, it is possible that this is also an important
source of RA that may prevent the severe early forebrain defects
observed in RAR antagonist-treated or vitamin A deficient chick
embryos. However, the genetic studies presented here suggest
that Raldh2 and Raldh3 are not required for early forebrain
regionalization. Raldh2−/−;Raldh3−/− double null embryos
carrying RARE-lacZ revealed that these two enzymes generate
all RA detectable rostrally during early stages of forebrain
development. Despite a complete loss of RA activity, Raldh2−/−;
Raldh3−/− embryos displayed relatively normal expression of
Fgf8 and Shh in the forebrain field at E8.75. In addition,
conditionally rescued Raldh2−/−;Raldh3−/− embryos (that still
lack RA in the early forebrain) exhibit normal expression of
Meis2 in the intermediate region of the telencephalon at E10.5.
Our previous studies on mouse embryos demonstrated that
RA generated by Raldh3 in the frontonasal surface ectoderm
does not reach the forebrain neuroectoderm (Mic et al., 2004).
As Raldh3 expression in chick embryos is quite similar,
RALDH3 is unlikely to be a source of RA for chick forebrain.
As rostral Raldh2 expression during early forebrain develop-
ment has been reported to be present only during presomite
stages in quail (Halilagic et al., 2003) but not until early somite
stages in mouse (Sirbu et al., 2005) and absent in chick (Blenticet al., 2003), Raldh2 does not appear to be an evolutionarily
conserved source of forebrain RA. We previously reported that
the early rostral Raldh2 expression domain for mouse that exists
in the optic vesicle neuroepithelium is unnecessary for eye
development, but that a later Raldh2 domain in the mesenchyme
adjacent to the optic vesicle is necessary for optic cup formation
(Molotkov et al., 2006). Importantly, this later mesenchymal
Raldh2 domain is conserved in chick (Blentic et al., 2003)
suggesting a conserved role for Raldh2 in eye development, but
our findings suggest that this mesenchymal Raldh2 expression
domain is unnecessary to establish Meis2 expression in the
forebrain.
We suggest that findings from studies utilizing RAR/RXR
antagonists may not reflect the physiological role of endoge-
nous RA as such compounds may have non-specific effects. As
RXRs are heterodimer partners for at least 10 nuclear receptors
other than RARs (Chawla et al., 2001), RAR and RXR
antagonists may block many important functions of RXR that
are independent of RA signaling. Furthermore, embryos that
lack RA due to vitamin A deficiency or a null mutation in
Raldh2 will suffer cardiovascular and somite defects that
gradually compromise overall embryonic survival (Dersch and
Zile, 1993; Lai et al., 2003; Niederreither et al., 1999), and this
may lead to non-specific effects on forebrain development at
later stages. Thus, compromised embryonic survival might
explain why Raldh2−/− embryos display normal expression of
Fgf8 and Shh expression in the forebrain field at E8.75, but
experience a reduction in expression at E9.5 (Ribes et al., 2006).
However, conditional RA treatment of Raldh2−/− embryos to
rescue overall embryonic survival will produce healthy embryos
at E9.5–E10.5 that still completely lack RA activity in the
forebrain; this method was used here for analysis of Meis2
expression.
Raldh3 expression in the frontonasal surface ectoderm does
not appear to have a function in early forebrain development,
Fig. 6. Raldh3 functions in a paracrine fashion to provide RA for control of Drd2 expression in the nucleus accumbens. (A–B) Loss of Drd2 expression in an E18.5
Raldh3−/− forebrain is specific for the nucleus accumbens; coronal sections through the left lobe are shown. (C) Forebrain Raldh3 expression in an E18.5 wild-type
coronal section (left lobe) comparable to that shown for Drd2 in panels A–B; Raldh3 is expressed in the subventricular zone of the ventral striatum positioned just
outside the nucleus accumbens in the dorsomedial direction. (D) RARβ expression at E18.5 in sections equivalent to those of panels A–C. (E–F) Comparison of
Raldh2 and RARβ mRNAs in sagittal sections through the forebrain at E18.5; Raldh3 expression occurs in a small domain along the anteroposterior axis near
the anterior end of the ventricle; RARβ expression is also localized to this same anteroposterior domain, but extends further ventrally than Raldh3 into the region
where the nucleus accumbens resides. ac, anterior commissure; cx, cortex; LGE, lateral ganglionic eminence; na, nucleus accumbens; ob, olfactory bulb; ot olfactory
tubercle; str, striatum; svz, subventricular zone.
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and those of others (Dupé et al., 2003) have shown that Raldh3
expression in the frontonasal surface ectoderm, which later
resolves into the olfactory pit ectoderm, is required to generate
RA that limits Fgf8 expression in the ventral olfactory pit.
Excessive Fgf8 expression in this location may play a role in
the development of nasal passage blockage in Raldh3−/−
embryos that results in lethality soon after birth (Dupé et al.,
2003); we have also observed the same lethal effect in our strain
of Raldh3−/− mice. As RA has been found to antagonize Fgf8
expression in other locations, particularly the node ectoderm
and posterior neural plate (Sirbu and Duester, 2006), RA
antagonism of Fgf8 may represent a common mechanism of
RA action. In contrast, chick embryos treated with the RA
synthesis inhibitor citral were reported to have decreased Fgf8
expression in the olfactory pit suggesting that RA may induce
Fgf8 (Song et al., 2004). However, RALDH inhibitors such
as citral or disulfiram may affect metabolism of compounds
other than retinoids as the three RALDHs are members of a
family containing 15 additional aldehyde dehydrogenases with
functions other than RA synthesis, and these enzymes may also
be inhibited by citral and disulfiram (Sophos and Vasiliou,
2003).
Previous studies on RAR double null mutants concluded that
RA signaling is required for proper development of the
hindbrain neuroepithelium leading to closure of the rhomben-
cephalon by E10.5; such a failure impairs the accumulation of
cerebrospinal fluid in the ventricular system leading toabnormal folding of the forebrain neuroepithelium observed at
E11.5 (Lohnes et al., 1994). Studies on RAR/RXR compound
null mutants reported no effect on forebrain development
(Kastner et al., 1994). Thus, a specific requirement for RA
signaling in the early forebrain neuroepithelium (up to E11.5)
has not been supported by examination of RAR and RXR
mutants. Other studies have suggested the possibility of an RA-
independent function for RARs during early forebrain devel-
opment as these receptors can, in the absence of ligand, recruit
corepressor complexes that may keep a nearby gene silent
(Weston et al., 2003). This possibility has not been ruled out by
previous studies on RAR null mutants, nor by our studies which
have removed the ligand.
Instead of an early role in forebrain development, our
findings suggest that RA plays a late role. Adult mice carrying
double null mutations of RARβ, RXRβ, or RXRγ were
previously found to exhibit impaired locomotion and reduced
expression of dopamine receptors in the ventral and medial
striatum, thus uncovering a potential late role for RA in the
forebrain (Krezel et al., 1998). Other studies found that the
dopamine receptor D2 (Drd2) promoter contains a retinoic
response element that binds RAR–RXR heterodimers and
stimulates RA-inducible transcription (Samad et al., 1997).
Drd2 is expressed throughout much of the striatum with very
high levels ventrally and medially in the nucleus accumbens (Lu
et al., 1998), a tissue where it has striking neurobehavioral
effects as demonstrated by the observation that Drd2−/− mice
exhibit Parkinsonian-like locomotor defects (Baik et al., 1995).
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loss of Drd2 expression in the nucleus accumbens and a
reduction in medial striatum. Such a loss would presumably
affect development of the neuronal circuits needed for proper
locomotor control. Further studies are needed to determine if
specific neurons in the nucleus accumbens are lost in the
absence of RA or whether neurons are retained but lose Drd2
expression. This effect of RA on Drd2 expression is likely to
exist only during forebrain development as Raldh3 expression
in the ventral telencephalon is not observed after postnatal day
15 (Wagner et al., 2002). Thus, our findings suggest that the
locomotor defects observed in adult RAR–RXR double mutants
(Krezel et al., 1998) may be due to defective development of the
nucleus accumbens rather than a requirement for RA signaling
in the adult striatum.
Gsh2 encodes a homeobox gene that specifies ventral
character in the telencephalon important for normal striatal
development (Yun et al., 2001). Gsh2−/− embryos exhibit a
large reduction in Raldh3 expression in the striatum (Waclaw et
al., 2004) and Gsh1−/−;Gsh2−/− embryos exhibit a complete
loss of striatal Raldh3 expression (Toresson and Campbell,
2001). As Gsh2−/− embryos also display a loss of Drd2
expression in the nucleus accumbens (Corbin et al., 2000), our
results suggest that this may be due to reduced Raldh3
expression observed in Gsh2−/− embryos.
Our studies on Raldh3 and RARβ expression in wild-type
and Raldh3−/− embryos indicate that the ventral striatum is a
robust site of RA signaling. Within this region (nucleus
accumbens) we suggest that Drd2 is a direct target of RA
signaling; this is supported by previous studies demonstrating a
retinoic acid response element in the Drd2 promoter (Samad et
al., 1997). Our observation that RA synthesis by Raldh3 in the
ventral subventricular zone is required to regulate Drd2
expression in the nucleus accumbens is another example of
paracrine signaling in which the source of RA synthesis is
distinct from the responding target tissue. RA has been found to
function exclusively in a paracrine fashion in several other
tissues including the optic cup and perioptic mesenchyme
(Molotkov et al., 2006), node ectoderm (Sirbu and Duester,
2006), hindbrain (Sirbu et al., 2005), spinal cord (Molotkova et
al., 2005), and pancreas (Molotkov et al., 2005; Stafford et al.,
2006).
In conclusion, our genetic studies demonstrate that RA is not
required to regulate early patterning of the forebrain as
previously suggested from inhibitor studies. Instead, we find
that the role of RA during forebrain development begins much
later during generation of specific neurons of the ventral
forebrain. Our studies point out the importance of utilizing
genetic loss-of-function studies to identify RA target tissues and
RA target genes.
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